Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Nystatin, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Eligibility Criteria
Inclusion Criteria Patients must have the following: Positive HIV antibody test. Diagnosis of AIDS-related complex (ARC). CD4+ cell count between 100 and 300 cells/mm3. Estimated life expectancy of at least 6 months. Normal neurological status. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Active opportunistic infection requiring ongoing therapy except patients being treated topically for oral thrush. Patients with the following are excluded: Active opportunistic infection. Known hypersensitivity to polyene antibiotics. Unwillingness to sign an informed consent or to be in compliance of protocol requirements. Prior Medication: Excluded within 72 hours of study entry: Biologic response modifier agents. Corticosteroids. Cytotoxic chemotherapeutic agents. Potential nephrotoxins. Potential neutropenic agents. Rifampin or rifampin derivatives. Systemic anti-infectives. Phenytoin or barbiturates (inducers of microsomal enzymes). All systemic medications. Prior Treatment: Excluded within 72 hours prior to study entry: Radiation therapy. Active alcohol or drug abuse unless they have been off drugs and/or alcohol for two weeks prior to start of study.
Sites / Locations
- Twelve Oaks Hosp